Yohei Doi MD
Assistant Professor, Medicine, University of Pittsburgh School of Medicine
Join to View Full Profile
3601 5th Ave"# Falk"Pittsburgh, PA 15213
Phone+1 412-648-6401
Fax+1 412-648-6399
Join Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Yohei Doi, MD is an infectious disease specialist in Pittsburgh, Pennsylvania. He is currently licensed to practice medicine in Pennsylvania. He is an Assistant Professor at University of Pittsburgh School of Medicine.
Education & Training
UPMC Medical EducationFellowship, Infectious Disease, 2005 - 2008
Icahn School of Medicine at Mount Sinai/Morningside/WestResidency, Internal Medicine, 2003 - 2005
Nagoya University - School of MedicineClass of 1998
Certifications & Licensure
PA State Medical License 2005 - 2026- PA State Medical License 2008 - 2026
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Infectious Disease
Publications & Presentations
PubMed
- Molecular Epidemiology and Clinical Characterization of Carbapenemase-Producing Enterobacter Species From an International Cohort.Jianping Jiang, Lauren Komarow, Carol Hill, Angelique E Boutzoukas, Blake Hanson
The Journal of Infectious Diseases. 2025-07-11 - Phenotypic and in silico characterization of carbapenem-resistant Serratia marcescens clinical strains.Anelise Stella Ballaben, Otávio G G de Almeida, Joseane Cristina Ferreira, Doroti de Oliveira Garcia, Yohei Doi
Journal of Global Antimicrobial Resistance. 2025-05-01 - In vitro activity of aztreonam in combination with relebactam against gram-negative pathogens producing various serine and metallo-β-lactamases.Kengo Hayashi, Masahiro Suzuki, Yoshikazu Ishii, Yasufumi Matsumura, Kazuaki Matsumoto
Journal of Global Antimicrobial Resistance. 2025-05-01
Press Mentions
Fujita Health University Favipiravir Trial Evidences No Statistically Conclusive Benefit to COVID-19 Patients: A Question Mark for Favipiravir?July 11th, 2020- WHO Studies File International Each Day Coronavirus Circumstances Improve: LiveJuly 10th, 2020
No Pause in Coronavirus Trial for Avigan, Japan's Lead Researcher SaysMay 20th, 2020- Join now to see all
Grant Support
- Colistin resistance in extensively drug-resistant Gram-negative pathogensUNIVERSITY OF PITTSBURGH AT PITTSBURGH2014–2025
